Ketohexokinase Isoforms in Endometrial Cancer.

Last updated: September 14, 2023
Sponsor: Far Eastern Memorial Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Endometrial Cancer

Vaginal Cancer

Pelvic Cancer

Treatment

ketohexokinase

Clinical Study ID

NCT03931265
108009-F
  • Ages > 20
  • Female

Study Summary

Our preliminary analysis with clinical database suggested that, in patients with type I endometrial cancer, high ketohexokinase-expressing group have lower survival probabilities than low ketohexokinase-expressing group. To understand the importance of ketohexokinase expression and isoform switch during the development of type I endometrial cancer, we propose a series of in vitro experiments and clinical examinations in this project.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • >20 years
  • Women with endometrial cancer who are about to be admitted to hospital forgynecological staging.
  • Women who have undergone gynecological staging surgery for endometrial cancer in thepast.

Exclusion

Exclusion Criteria:

  • Women with endometrial cancer who receive preoperative chemotherapy or radiationtherapy.

Study Design

Total Participants: 220
Treatment Group(s): 1
Primary Treatment: ketohexokinase
Phase:
Study Start date:
April 11, 2019
Estimated Completion Date:
December 31, 2024

Connect with a study center

  • Department of Obstetrics and Gynecology, Far-Eastern Memorial Hospital

    Banqiao, New Taipei 22050
    Taiwan

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.